The history of vaccines traces a path from folk observations to molecular precision, marking one of humanity’s greatest achievements in public health. For centuries, infectious diseases shaped the course of civilizations, often claiming more lives than wars. The deliberate use of biological material to induce protection against a deadly pathogen began with a country doctor’s daring experiment in 1796, and has since evolved into a sophisticated scientific discipline. Today, vaccines prevent an estimated 3.5–5 million deaths each year, a figure that underscores both the legacy and the promise of immunization. This narrative of innovation and resilience reveals how the interplay between careful observation, rigorous science, and global cooperation has repeatedly turned the tide against infectious threats.

Early Beginnings and Edward Jenner's Pioneering Work

Long before Edward Jenner, different cultures practiced a form of protective exposure known as variolation. As early as the 10th century in China, dried smallpox scabs were ground and inhaled or introduced into small cuts in the skin. The practice spread along trade routes to India, the Ottoman Empire, and eventually to Europe in the early 18th century, popularized by Lady Mary Wortley Montagu. Variolation had a significant drawback: it caused a mild form of smallpox that still carried a risk of severe disease or death, and the inoculated person could transmit the illness to others. The case fatality rate was around 2–3%, compared to 20–30% for natural smallpox, but a safer method was desperately needed.

Edward Jenner, a physician in rural Gloucestershire, England, became intrigued by a local belief that dairymaids who had contracted cowpox, a mild disease transmitted from cattle, were immune to smallpox. Jenner was not the first to hear this lore, but he was the first to test it systematically. On May 14, 1796, he took fluid from a cowpox pustule on the hand of milkmaid Sarah Nelmes and inoculated eight-year-old James Phipps. The boy developed a mild fever and a local lesion but recovered quickly. Six weeks later, Jenner variolated the child with smallpox material, and no disease ensued. He repeated the experiment on other children, including his own infant son, documenting the results meticulously.

Jenner named the process “vaccination” from the Latin vacca for cow, and published his findings in the pamphlet An Inquiry into the Causes and Effects of the Variolae Vaccinae in 1798. The medical establishment initially met his work with skepticism and ridicule; many physicians were reluctant to accept that an animal disease could protect against a human one. Nonetheless, the advantages were soon apparent. Vaccination was far safer than variolation, and it did not cause outbreaks. Within a few years, the practice spread throughout Europe and across the Atlantic. Thomas Jefferson, an early advocate, vaccinated his family and encouraged the procedure among Native American nations. By 1800, vaccination had reached North America and the Caribbean.

Jenner’s genius lay not only in his empirical demonstration but also in his vision of a world free from smallpox. He never patented his discovery, choosing instead to share the knowledge freely. This ethical tradition of broad dissemination would echo through later vaccine pioneers. Despite early resistance, including satirical cartoons showing people sprouting cow parts, vaccination campaigns gained momentum, laying the groundwork for the worldwide eradication of smallpox nearly two centuries later. Jenner’s work established the core principle of immunization: exposing the immune system to a harmless form of a pathogen can confer durable protection against the dangerous form.

To read more about the early history of smallpox and vaccination, visit the Centers for Disease Control and Prevention’s smallpox history page and the World Health Organization’s vaccination timeline.

Expansion of Vaccination in the 19th and Early 20th Centuries

The century after Jenner’s breakthrough saw slow but steady scientific progress. The next major leap came from Louis Pasteur in France, who built on Jenner’s concept but expanded it to other diseases. Pasteur’s work on germ theory in the 1860s proved that microorganisms cause disease, providing a theoretical framework for vaccine design. In 1879, while studying fowl cholera, Pasteur serendipitously discovered that aging bacterial cultures lost virulence while retaining the ability to induce protection. He called this an attenuated vaccine, and he quickly applied the principle to anthrax, a disease devastating livestock.

Pasteur’s public demonstration of the anthrax vaccine in 1881 at Pouilly-le-Fort was a spectacle of scientific triumph. He vaccinated half of a flock of sheep and left the other half as controls. When both groups were challenged with live anthrax bacteria, the vaccinated animals survived while the unvaccinated perished. The dramatic result captured public imagination and legitimized vaccination as a powerful tool against bacterial diseases.

Pasteur’s most celebrated human vaccine followed. In 1885, he developed a vaccine for rabies, a horrific and invariably fatal disease. Though he did not know the causative virus, Pasteur grew the pathogen in rabbit nerve tissue and dried the spinal cords to attenuate it. When nine-year-old Joseph Meister was bitten by a rabid dog, Pasteur administered a series of injections, and the boy survived. The successful treatment attracted worldwide attention, leading to the establishment of the Pasteur Institute, which became a center for vaccine research and production.

During this same period, other researchers created vaccines against cholera, typhoid, and plague. Waldemar Haffkine, a Russian scientist working in India, developed the first cholera vaccine in 1892 and a plague vaccine in 1897, often testing them on himself before administering to others. Emil von Behring and Shibasaburo Kitasato developed serum therapy for diphtheria and tetanus, demonstrating that antibodies from immunized animals could provide passive immunity. By the early 20th century, diphtheria antitoxin was saving tens of thousands of lives. The later development of the diphtheria toxoid vaccine by Gaston Ramon in the 1920s turned a toxin into a safe immunogen, paving the way for modern combination vaccines.

Vaccination campaigns grew in scale, but they were not without opposition. In England, the Compulsory Vaccination Act of 1853 mandated smallpox vaccination for infants, igniting fierce resistance from anti-vaccination leagues. Critics argued that the state had no right to violate bodily autonomy, and some feared the introduction of “animal impurities” into the blood. Organized opposition delayed vaccination coverage, but public health advocacy and improved vaccine purity standards gradually increased acceptance. The experience foreshadowed modern debates over vaccine mandates and individual rights—a tension that persists in the 21st century.

Scientific Foundations: Germ Theory and Immunological Mechanisms

The transition from empirical vaccine development to rational design relied on a deeper understanding of the immune system. The discovery of antibodies in the 1890s and the conceptualization of cellular immunity by Élie Metchnikoff opened new avenues. By the 1930s, researchers could visualize the interaction between antigens and antibodies, and they understood that immunity involves both humoral (antibody-mediated) and cellular components. This knowledge informed the development of more targeted vaccines and the assessment of their potency.

Key to the refinement of vaccines was the ability to grow pathogens outside the body. In the 1920s and 1930s, advances in tissue culture and egg-based cultivation enabled the large-scale production of viruses. The yellow fever vaccine, developed by Max Theiler in 1937, relied on attenuated virus grown in chicken eggs—a method that would later be used for influenza. Theiler’s work earned a Nobel Prize and provided a model for viral vaccine production that dominated for decades. The understanding of viral mutation and serotype diversity also emerged, explaining why some vaccines needed seasonal updates, most notably for influenza.

Research into immunological memory revealed that vaccines work by mimicking natural infection without causing illness. The initial exposure primes lymphocytes to generate memory B cells and T cells, which patrol the body for years. Upon encountering the real pathogen, these memory cells rapidly proliferate and mount a robust defense, often neutralizing the threat before symptoms arise. This fundamental principle underlies the effectiveness of all vaccines, from the oldest live attenuated preparations to modern mRNA platforms.

Technological Advances: From Inactivated to Recombinant Vaccines

The 20th century witnessed an explosion of vaccine technologies. Inactivated vaccines, which use killed whole organisms, were pioneered for typhoid and cholera, and later for pertussis. In the 1950s, Jonas Salk developed an inactivated polio vaccine (IPV) that was tested in a massive field trial involving nearly two million children. Salk’s vaccine was declared safe and effective in 1955, prompting nationwide vaccination drives that slashed polio incidence. Almost simultaneously, Albert Sabin developed a live attenuated oral polio vaccine (OPV) that was easier to administer and induced strong gut immunity. Sabin’s vaccine became the backbone of global eradication efforts, though the rare risk of vaccine-associated paralytic polio eventually led many countries to return to IPV.

Vaccination against childhood diseases expanded dramatically. The measles vaccine, licensed in 1963, and the subsequent development of the combined measles-mumps-rubella (MMR) vaccine in 1971, dramatically reduced the burden of these once-ubiquitous infections. Prior to the measles vaccine, an estimated 2.6 million children died from the disease each year; by 2021, global measles vaccination had prevented over 56 million deaths, according to the World Health Organization.

The late 20th century brought subunit and conjugate vaccines, which use only specific fragments of a pathogen to stimulate immunity. The hepatitis B vaccine, licensed in 1986, was the first recombinant vaccine: the viral surface antigen was produced in genetically engineered yeast cells, eliminating any risk of live virus. It also became the first vaccine to prevent a human cancer, as chronic hepatitis B is a leading cause of liver cancer. The introduction of conjugate vaccines, which chemically link polysaccharide antigens to protein carriers, transformed the fight against bacterial infections in young children. The Haemophilus influenzae type b (Hib) conjugate vaccine, introduced in the early 1990s, virtually eliminated a disease that had been the leading cause of bacterial meningitis in children under five in many countries. Pneumococcal and meningococcal conjugate vaccines further reduced the incidence of invasive bacterial disease.

The human papillomavirus (HPV) vaccine, licensed in 2006, exemplifies the cancer-preventing potential of vaccines. By targeting the viral strains responsible for the majority of cervical and other genital cancers, the HPV vaccine has already led to dramatic declines in precancerous cervical lesions in countries with high coverage. A comprehensive list of vaccine-preventable diseases and their histories can be found on the History of Vaccines project by the College of Physicians of Philadelphia.

The Modern Era: Genetic Vaccines and Rapid Response

The most transformative shift in vaccine technology arrived with the harnessing of genetic information. Conventional vaccines require growing large quantities of a pathogen or its components, a process that can take months or years. Genetic vaccines bypass this entirely by delivering the genetic instructions that teach the body’s own cells to produce a specific antigen. The immune system then responds to this self-made protein, generating both antibodies and cellular immunity.

DNA vaccines, investigated since the 1990s, showed promise in animal models but faced challenges in generating robust immune responses in humans. The breakthrough came with messenger RNA (mRNA) technology. For decades, scientists knew that mRNA, the transient intermediate between DNA and protein, could theoretically be used as a therapeutic, but its instability and tendency to trigger inflammation were significant hurdles. In the early 2000s, researchers Katalin Karikó and Drew Weissman discovered that modifying one of the nucleosides in mRNA could abrogate the unwanted inflammatory reaction while preserving the protein-coding function. This foundational work, for which they received the 2023 Nobel Prize in Physiology or Medicine, unlocked the platform.

The first COVID-19 vaccines, developed by Pfizer-BioNTech and Moderna, were the culmination of years of mRNA research. When the SARS-CoV-2 genome was published in January 2020, vaccine engineers could design mRNA constructs within days, encoding the spike protein. Clinical trials moved at unprecedented speed, and within eleven months, the first doses were being administered under emergency use authorization. The vaccines demonstrated approximately 95% efficacy against symptomatic COVID-19 in initial trials and were later adapted to emerging variants. This rapid-response capability has redefined pandemic preparedness; the same platform can be reprogrammed for influenza, Zika, rabies, or any pathogen with a known protein target.

Viral vector vaccines, such as those developed by the University of Oxford/AstraZeneca and Johnson & Johnson, use harmless modified viruses (typically adenoviruses) to deliver gene instructions for an antigen. Though not new in concept—viral vectors had been explored for HIV and Ebola vaccines—the COVID-19 pandemic propelled them into mass use. The combination of mRNA, viral vector, and traditional inactivated vaccines created the largest and most diverse immunization campaign in history, with over 13 billion doses administered globally by early 2023. For a detailed review of these technologies, the Nature Reviews Drug Discovery article on COVID-19 vaccine platforms offers an accessible yet rigorous overview.

Global Health Impact and Persistent Challenges

The eradication of smallpox stands as the ultimate validation of vaccination. In 1967, the WHO launched an intensified global eradication program, using targeted ring vaccination strategies. The last natural case occurred in Somalia in 1977, and in 1980 the World Health Assembly declared the disease eradicated. No other human disease has been deliberately wiped from the planet, though polio is tantalizingly close. The Global Polio Eradication Initiative, begun in 1988, has driven wild poliovirus cases down by more than 99%, from an estimated 350,000 cases across 125 countries to just a handful of cases annually in the two remaining endemic countries, Afghanistan and Pakistan. The effort has been complicated by conflict, vaccine-derived outbreaks from OPV, and logistical barriers, but the scientific foundation is solid: polio can be eradicated.

Vaccines have reduced childhood mortality from measles, diphtheria, pertussis, and tetanus to historically low levels. The WHO estimates that global immunization programs save millions of lives each year and are a cornerstone of primary health care. The introduction of vaccines against rotavirus and pneumococcal pneumonia has further reduced deaths from diarrhea and respiratory infections, the two biggest killers of young children in low-income countries.

Yet profound challenges remain. Vaccine hesitancy, amplified by misinformation and mistrust, threatens to undermine decades of progress. The rapid spread of unfounded claims about vaccine safety, particularly regarding the MMR vaccine and autism, caused measles vaccination rates to drop in several high-income countries, leading to resurgent outbreaks. Social media exacerbates the problem, making it easier for false narratives to travel faster than scientific evidence. Addressing hesitancy requires empathetic communication, transparency about adverse events, and engagement with community leaders.

Equitable access is another pressing concern. While high-income countries rolled out COVID-19 booster doses, many low-income nations waited months for first doses. The divide reflects systemic inequities in manufacturing capacity, financing, and health infrastructure. Organizations like Gavi, the Vaccine Alliance, and the Coalition for Epidemic Preparedness Innovations (CEPI) work to close these gaps, but the COVID-19 experience underscored the need for regional vaccine production hubs and more predictable funding.

Researchers are now pursuing “universal” vaccines that provide broad protection against all subtypes of influenza, eliminating the need for annual reformulation. Similarly, a universal coronavirus vaccine could provide defense against future spillovers. Efforts to develop effective vaccines against HIV, tuberculosis, and malaria have seen both disappointments and breakthroughs. The RTS,S malaria vaccine, a result of decades of research, was recommended by the WHO in 2021 for children in sub-Saharan Africa, where it can prevent life-threatening disease. An even more promising R21/Matrix-M vaccine followed in 2023, marking a turning point in the fight against a parasite that kills over half a million people each year. Resources at the Gavi website detail ongoing vaccine initiatives and access programs.

The Road Ahead

Vaccine science now integrates computational biology, structural vaccinology, and nanotechnology. Scientists can design immunogens that present precisely the right molecular shape to elicit neutralizing antibodies, as seen with the respiratory syncytial virus (RSV) vaccines approved in 2023. Needle-free delivery methods, such as microarray patches and nasal sprays, promise easier administration and better mucosal immunity, which could help stop transmission of respiratory pathogens at their point of entry.

The future of vaccines also depends on strengthening surveillance systems that can detect emerging pathogens early and link genetic sequence data to rapid vaccine design. The 100 Days Mission, championed by CEPI, aims to shorten the time from pathogen identification to the availability of licensed vaccines to just over three months. If successful, such a capability would fundamentally change humanity’s relationship with pandemic threats, making them manageable disruptions rather than catastrophic events.

Ultimately, the history of vaccines is a story of cumulative progress—each discovery built upon the last, each success inspiring the next generation of researchers. From a Gloucestershire milkmaid’s pustule to a lipid nanoparticle carrying synthetic mRNA, the thread of innovation runs unbroken. As long as pathogens evolve and new diseases emerge, the quest for better, more accessible vaccines will continue, driven by the same combination of curiosity, compassion, and rigorous science that guided Edward Jenner more than two centuries ago.